What's new in hormone replacement therapy: Focus on transdermal estradiol and micronized progesterone

Climacteric

Volumn 15, Issue SUPPL.1, 2012, Pages 3-10

  Simon, J A ^a  

^a GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

ADVERSE EVENTS; GUIDELINES; HORMONE REPLACEMENT THERAPY; MICRONIZED PROGESTERONE; THROMBOEMBOLIC DISEASE; TRANSDERMAL ESTRADIOL; VENOUS THROMBOEMBOLISM

Indexed keywords

ESTRADIOL; PROGESTERONE;

ARTICLE; BRAIN ISCHEMIA; BREAST CANCER; CANCER RISK; CHOLECYSTITIS; DRUG EFFICACY; FAMILY HISTORY; GROUPS BY AGE; HORMONE SUBSTITUTION; HUMAN; OBESITY; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; RISK REDUCTION; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, CUTANEOUS; AGE FACTORS; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; POSTMENOPAUSE; PROGESTERONE; VENOUS THROMBOEMBOLISM;

EID: 84858787111     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2012.669332     Document Type: Article

References (38)

1. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33 (Pubitemid 34761611)
2. Cushman M, Kuller LH, Prentice R, et al. Estrogen plus progestin and risk of venous thrombosis. JAMA 2004;292:1573-80 (Pubitemid 39314963)
3. Curb JD, Prentice RL, Bray PF, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. Arch Intern Med 2006;166:772-80
4. Wassertheil-Smoller S, Hendrix SL, Limacher M, e t al . Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA 2003;289:2673-84 (Pubitemid 37430138)
5. Chlebowski RT, Hendrix SL, Langer RD, et al. Infl uence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative randomized trial. JAMA 2003;289:3243-53 (Pubitemid 37430077)
6. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349: 523-34 (Pubitemid 36951364)
7. Hendrix SL, Wassertheil-Smoller S, Johnson KC, e t al . Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation 2006;113:2425-34 (Pubitemid 43948050)
8. Hsia J, Langer RD, Manson JE, et al. Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med 2006;166:357-65 (Pubitemid 43244325)
9. Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701-12 (Pubitemid 38489892)
10. Rossouw JE, Prentice RL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-77 (Pubitemid 46556472)
11. Hersh AL, Stefanick ML, Stafford RS. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 2004;291:47-53 (Pubitemid 38040534)
12. Information derived by Bayer HealthCare from data provided by Wolters Kluwer Health, Source(R) Retail data; 2001-2008
13. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. Menopause 2010;17:242-55
14. Santen RJ, Allred DC, Ardoin SP, et al. Postmenopausal hormone therapy: an Endocrine Society scientifi c statement. J Clin Endocrinol Metab 2010;95(7 Suppl 1):s1-66
15. Sturdee DW, Pines A; International Menopause Society Writing Group. Updated IMS recommendations on postmenopausal Ingelheim, EndoCeutics Inc., Novo Nordisk, Novogyne, and Teva Pharmaceutical Industries Ltd. He has also served on the speakers ' bureaus of: Amgen Inc., Ascend Therapeutics, Bayer, Boehringer Ingelheim, Merck, Novartis, Novo Nordisk, Novogyne, Teva Pharmaceutical Industries Ltd, and Warner Chilcott. Source of funding The content of this article was based on a presentation given at a symposium, sponsored by Besins Healthcare, at the 2011 World Congress on Menopause of the International Menopause Society. hormone therapy and preventive strategies for midlife health. Climacteric 2011;14:302-20
16. Tremollieres F, Brincat M, Erel CT, e t al . EMAS position statement: Managing menopausal women with a personal or family history of VTE. Maturitas 2011;69:195-8
17. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation 2007;115:840-5 (Pubitemid 46294724)
18. OliéV, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol 2010;17:457-63
19. Canonico M, Fournier A, Carcaillon L, e t al . Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol 2010;30:340-5
20. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a populationbased study. J Thromb Haemost 2010;8:979-86
21. Canonico M, Bouaziz E, Carcaillon L, et al. Synergism between oral estrogen therapy and cytochrome P450 3A5 * 1 allele on the risk of venous thromboembolism among postmenopausal women. J Clin Endocrinol Metab 2008;93:3082-7
22. Canonico M, Plu-Bureau G, Lowe GD, Scarabin PY. Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis. BMJ 2008;336:1227-31 (Pubitemid 351809317)
23. Straczek C, Oger E, Yon de Jonage-Canonico MB, e t al . Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. Circulation 2005;112:3495-500 (Pubitemid 43739566)
24. Canonico M, Oger E, Conard J, et al. Obesity and risk of venous thromboembolism among postmenopausal women: differential impact of hormone therapy by route of estrogen administration. The ESTHER Study. J Thromb Haemost 2006; 4:1259-65
25. Scarabin PY, Oger E, Plu-Bureau G; EStrogen and THrombo- Embolism Risk Study Group. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet 2003;362:428-32 (Pubitemid 36999704)
26. Canonico M, Alhenc-Gelas M, Plu-Bureau G, OliéV, Scarabin PY. Activated protein C resistance among postmenopausal women using transdermal estrogens: importance of progestogen. Menopause 2010;17:1122-7
27. Post MS, Christella M, Thomassen LG, et al. Effect of oral and transdermal estrogen replacement therapy on hemostatic varia bles associated with venous thrombosis: a randomized, placebocontrolled study in postmenopausal women. Arterioscler Thromb Vasc Biol 2003;23:1116-21 (Pubitemid 36713570)
28. Oger E, Alhenc-Gelas M, Lacut K, e t al . Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003;23: 1671-6 (Pubitemid 37108215)
29. M ueck AO. Postmenopausal hormone replacement therapy and cardiovascular disease: the value of transdermal estradiol and micronized progesterone. Climacteric 2012;15(Suppl 1):11-17
30. Gompel A. Micronized progesterone and its impact on the endometrium and breast vs. progestogens. Climacteric 2012; 15(Suppl 1):18-25
31. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. Arch Intern Med 2008;168:861-6 (Pubitemid 351620088)
32. Bath PM, Gray LJ. Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ 2005; 330:342
33. Arana A, Varas C, González-P érez A, Gutiérrez L, Bjerrum L, García Rodríguez LA. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause 2006;13:730-6 (Pubitemid 44435027)
34. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. BMJ 2010;340:c2519
35. Liu B, Beral V, Balkwill A, e t al . Gallbladder disease and use of transdermal versus oral hormone replacement therapy in postmenopausal women: prospective cohort study. BMJ 2008; 337:a386
36. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA 2010; 303:2355-41
37. de Lauzon-Guillain B, Fournier A, Fabre A, et al. Menopausal hormone therapy and new-onset diabetes in the French Etude Epidemiologique de Femmes de la Mutuelle G én érale de l'Education Nationale (E3N) cohort. Diabetologia 2009;52:2092-100
38. The North American Menopause Society. The 2012 Hormone Therapy Position Statement of the North American Menopause Society. Menopause 2012;19:257-71